Physician profile
Michael Patrick Gannon
NPI 1194086041
$847.02
in general payments reported to CMS, 2019-2025
14 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.87 · 2024: $300 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.42 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.36 | 2024-2025 | Jardiance |
| Amgen INC. | $111.70 | 2024-2025 | Repatha, Repatha |
| Heartflow, INC. | $110.53 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.93 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $34.03 | 2025 | Verquvo |
| Pfizer INC. | $33.17 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $32.62 | 2023-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $31.45 | 2025 | |
| Edwards Lifesciences Corporation | $21.31 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $19.93 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.54 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $17.78 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $15.25 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.